Trinity Biotech Plc :TRIB-US: Earnings Analysis: 2016 By the Numbers : May 1, 2017

Trinity Biotech Plc reports financial results for the year ended December 31, 2016.

We analyze the earnings along side the following peers of Trinity Biotech Plc – Quidel Corporation, Abbott Laboratories, Thermo Fisher Scientific Inc. and Danaher Corporation (QDEL-US, ABT-US, TMO-US and DHR-US) that have also reported for this period.


  • Gross margins narrowed from 43.51% to 40.67% compared to the same period last year, operating (EBITDA) margins now 9.68% from 18.77%.
  • Year-on-year change in operating cash flow of -48.51% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Earnings rose compared to same period last year, despite decline in operating and pretax margins.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2016 2015 2014 2013 2012
Relevant Numbers (Annual)
Revenues 99.32 99.66 103.28 91.28 81.92
Revenue Growth (YOY) N/A N/A N/A N/A N/A
Earnings -38.47 21.68 16.95 9.65 17.22
Earnings Growth (YOY) -277.46 27.88 75.62 -43.94 10.19
Net Margin -38.73 21.75 16.41 10.57 21.02
EPS -4.39 0.48 0.71 0.4 0.75
Return on Equity -23.8 10.71 9.06 5.44 10.66
Return on Assets -12.52 7.24 7.34 4.53 9.27

Access our Ratings and Scores for Trinity Biotech Plc

Earnings Growth Analysis

The company’s year-on-year decline in earnings was influenced by a weakening in gross margins from 43.51% to 40.67%, as well as issues with cost controls. As a result, operating margins (EBITDA margins) went from 18.77% to 9.68% in this time frame. For comparison, gross margins were 43.51% and EBITDA margins were 18.77% in the previous period.

Gross Margin Versus EBITDA Margin

Quadrant label definitions. Hover to know more

Differentiated; Low Cost, Commodity; Low Cost, Commodity; High Cost, Differentiated; High Cost

Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

TRIB-US‘s decline in gross margins has not produced any significant offsetting improvement in its working capital . This leads Capital Cube to conclude that the decline in gross margins are likely from operating issues and not trade-offs with the balance sheet. Working capital days are currently 462.84 days, compared to last year’s level of 345.31 days.

Gross Margin Versus Working Capital Days

Quadrant label definitions. Hover to know more

Customer Financed, Cash Starved, Supplier Financed, Cash Rich

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

TRIB-US‘s change in operating cash flow of -48.51% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Cash Flow based Earnings, Likely Non-cash Earnings, Low Cash Flow Base, Likely Undeclared Earnings


Despite a decline in operating (EBIT) margins as well as a decline in pretax margins, the company’s earnings rose.

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Trinity Biotech Plc

Company Profile

Trinity Biotech Plc develops, manufactures and markets diagnostic test kits for the clinical laboratory. Its products are used to detect autoimmune, infectious and sexually transmitted diseases, autoimmune disorders, cardiac arrest, haemoglobin disorders, diabetes and disorders of the liver and intestine.The company was founded by Ronan O’Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of TRIB-US.